Mutation in the GRN gene, encoding the progranulin (PGRN) protein, shows a dose-dependent disease correlation, wherein haploinsufficiency results in frontotemporal lobar degeneration (FTLD) and complete loss results in neuronal ceroid lipofuscinosis (NCL). Although the exact function of PGRN is unknown, it has been increasingly implicated in lysosomal physiology. Here we report that PGRN interacts with the lysosomal enzyme, glucocerebrosidase (GBA), and is essential for proper GBA activity. GBA activity is significantly reduced in tissue lysates from PGRN-deficient mice. This is further evidence that reduced lysosomal hydrolase activity may be a pathological mechanism in cases of GRN-related FTLD and NCL.
Introduction
Progranulin (PGRN), encoded by the GRN gene in humans, is a glycoprotein comprised of 7.5 conserved and highly disulfide-bonded homologous granulin domains connected by short linker regions (1) (2) (3) (4) (5) (6) . While the exact function of PGRN remains elusive, it has been found to be involved in numerous normal physiologic and pathologic processes, including regulation of inflammation, wound healing, and tumorigenesis, and it has also been shown to function as a growth and neurotrophic factor (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Mutation in GRN has been linked to two neurodegenerative diseases with dose-dependent associations.
Heterozygous mutation, resulting in PGRN haploinsufficiency, is known to cause frontotemporal lobar degeneration (FTLD), a clinically and pathologically heterogeneous disease often resulting in early-onset dementia (17) (18) (19) (20) (21) (22) (23) . Homozygous mutation, resulting in complete loss of PGRN, causes neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease (24, 25) . Although these two diseases are distinct, NCL-related phenotypes have been reported in FTLD patients with GRN mutation, suggesting that lysosomal dysfunction might serve as a common mechanism (26-28).
In addition to the connection to NCL, increasing lines of evidence indicate that PGRN is likely to be involved in lysosomal physiology. In addition to being lysosomally localized, having two independent trafficking pathways to the lysosome (29, 30) , and being under transcriptional regulation with the majority of known lysosomal proteins (31) , PGRN has recently been shown to be proteolytically processed to produce stable and functional granulin peptides in the lysosome (32) (33) (34) , and is linked to the direct or indirect regulation of two lysosomal hydrolases, cathepsin D (CTSD) and glucocerebrosidase (GBA). PGRN was shown to stabilize and directly modulate the activity of cathepsin D in vitro and PGRN deficiency results in a reduction of cathepsin D activity in vivo (28, 35, 36) . In another study, PGRN was purported to be a co-chaperone of glucocerebrosidase (GBA) (37, 38) , a β-glucosidase mutated in Gaucher disease, in tandem with heat shock protein 70 (HSP70) (39) . Grn knockout mice with induced chronic inflammation display cellular phenotypes similar to those with Gaucher disease (37, 38) .
To better understand the lysosomal role of PGRN, we performed a stable isotope labeling by amino acids in cell culture (SILAC)-based proteomic screen for PGRN protein interactors. Corresponding with the previous findings, one of the top hits was GBA. In this study, we demonstrate that PGRN loss results in a substantial decrease in GBA activity in mouse tissues without any changes in protein levels.
Material and Methods

Primary Antibodies and Reagents
The following antibodies were used in this study: M2 mouse anti-FLAG (Sigma), M2 mouse anti-FLAGconjugated beads (Sigma), mouse anti-myc (9E10), mouse anti-GAPDH (Proteintech Group), mouse anti-GBA (MilliporeSigma), rat anti-mouse LAMP1 (BD Biosciences), and sheep anti-mouse PGRN (R&D Systems). Rabbit anti-mouse PSAP and PGRN antibodies were produced as previously described (30) , GFP-Trap beads (ChromoTek). 4-Methylumbelliferyl β-D-glucopyranoside (4-MU) GBA substrate (Sigma).
Plasmids
Human GBA cDNA in the pDONR223 vector from the human ORFeome 8.1 collection was a gift from Dr. Haiyuan Yu (Cornell University). GBA was cloned into pcDNA3.1/myc-His A vector (Thermo Fisher Scientific) after digestion with EcoRI and XhoI. Human PGRN in the pCMV-Sport6 vector was obtained as previously described (29) . GFP-PGRN was produced as previously described (30) . GFPgranulin peptides were produced as described (36) .
Protein Production and Purification
GST-granulin E, GST-granulin F and His-SUMO-saposin C proteins were expressed from Origami B(DE3) bacterial strains (MilliporeSigma) with 0.1 mM IPTG induction overnight at 18°C. Proteins were purified using GST or cobalt beads. His-PGRN was purified with cobalt beads from the culture media of HEK293T cells as previously described (30) . All purified proteins were concentrated and transitioned to PBS buffer with Centricon Centrifugal Filter Units (MilliporeSigma).
Mouse Strains
C57/BL6 and Grn -/mice (40) were obtained from The Jackson Laboratory. Gba -/mice were generated as previously described (41) . Mixed male and female mice were used for this study.
Cell Culture
HEK293T and BV2 cells were maintained in Dulbecco's Modified Eagle's Medium (Cellgro) supplemented with 10% fetal bovine serum (Gibco) in a humidified incubator at 37ºC with 5% CO 2 .
WT, Grn -/and Gba -/mouse fibroblasts were cultured as described (30) .
Transfection, Immunoprecipitation, and Western Blot Analysis
Cells were transfected with polyethylenimine as previously described (42) . Cells were lysed in a cold, near-neutral pH solution containing 150 mM NaCl, 50 mM Tris pH 7.5 or 50mM sodium acetate pH5.3, 1% Triton X-100, 0.1% deoxycholic acid, 1X protease inhibitors (Roche). After centrifugation at 14,000 xg, for 15 minutes, at 4°C, supernatants were transferred to clean tubes on ice, to which rabbit anti-PGRN antibody-conjugated Affi-Gel 15 (Bio-Rad Laboratories) or GFP-Trap beads were added, then rocked for 3-4 hours at 4ºC. Samples were run on 12% polyacrylamide gels or 4-12% Bis-Tris gels (Invitrogen), then transferred to Immobilon-FL polyvinylidene fluoride membranes (Millipore Corporation) or nitrocellulose membranes (Millipore Corporation). Membranes were blocked with either 5% non-fat milk in PBS or Odyssey Blocking Buffer (LI-COR Biosciences) for 1 hour then washed with Tris-buffered saline with 0.1% Tween-20 (TBST) 3x for 5 minutes each. Membranes were incubated with primary antibodies, rocking overnight at 4ºC, then washed as above, incubated with secondary antibodies for 2 hours at room temperature, then washed again. Membranes were scanned using an Odyssey Infrared Imaging System (LI-COR Biosciences). Densitometry was performed with Image Studio (LI-COR Biosciences).
Tissue Preparation for Enzyme Assays and Western Blot
Tissues from 2-month-old WT and Grn -/mice were homogenized on ice with a glass Dounce homogenizer in a cold solution of either 1% (w/v) sodium taurocholate and 1% (v/v) Triton X-100, pH 5.2, for 4-MU activity assays or 0.2% (w/v) sodium taurocholate and 0.1% (v/v) Triton X-100 for MDW941 assays. Protein concentrations were determined via Bradford assay, then standardized.
GBA Activity Assay with 4-MU Substrate
Tissue lysates, prepared as described, were diluted in a cold buffer of 0.1 M citric acid/0. 
Active GBA Assessment with MDW941 Probe
MDW941 was diluted to 100nM in tissue lysates, which were then incubated at 37ºC for 30 minutes.
Reactions were stopped by the addition of an equal volume of 2x Laemmli sample buffer with 10% β-Mercaptoethanol before heating at 95ºC for 5 minutes. An equal amount of each sample (50μg total protein) was run on a 12% polyacrylamide gel, which was scanned at 532 nm excitation/580 nm emission with a Typhoon Imaging System (GE Healthcare), then western blot and assessment were performed as described above, with all values normalized to GAPDH.
MDW941 Cell Labeling, Immunostaining, and Confocal Microscopy
WT and Grn-/-MEFs were cultured on glass coverslips overnight. The next day, MDW941 was diluted to 5 nM in culture media, then equal volumes were added to each well and the plate was incubated at 37ºC for 2 hours. Cells were washed 2x with PBS, fixed with 3.7% paraformaldehyde for 15 minutes at room temperature, followed by 3 additional PBS washes. Cells were permeabilized with Odyssey Blocking Buffer LI-COR Biosciences) + 0.05% saponin for 30 minutes at room temperature. Primary antibodies were diluted in the same buffer and added to coverslips, which were incubated in a humidified chamber overnight at 4ºC. Coverslips were washed 3x with PBS, for 5 minutes each, then secondary antibodies diluted in the same blocking/permeabilization solution were added to the coverslips, which were incubated at room temperature, in the dark, for 2 hours. After 3 additional PBS washes, coverslips were mounted on slides with Fluoromount-G (SouthernBiotech). Images were acquired with a CSU-X series spinning disc confocal microscope (Intelligent Imaging Innovations) with an HQ2 CCD camera (Photometrics) using a 100x objective. Mann-Whitney U test was used to calculate the p value to generate the volcano plot.
SILAC and Mass Spectrometry
Results
PGRN interacts with GBA
SILAC was performed in the murine microglia-derived BV2 cell line, with either normal PGRN expression or loss of PGRN expression after CRISPR/cas9 mediated genome editing (43, 44) ( Fig. 1a and   1b ). GBA was one of the high-confidence hits for PGRN from this experiment ( Fig. 1b) (Table S1 ).
To verify the physical interaction between PGRN and GBA, FLAG-PGRN and GBA with a Cterminal myc tag were co-transfected in HEK293T cells, then anti-PGRN immunoprecipitation (IP) was performed. GBA-myc signal was detected in the IP products from the PGRN transfected, but not control samples, indicating a specific binding interaction (Fig. 1c ). This interaction persists at pH5.3 (Fig. 1d ).
Additionally, PGRN has been shown to be processed into individual granulin peptides within the lysosome (32, 33) and two of these peptides, Grn E and Grn F, have been shown to interact with GBA (37, 38) . Since both PGRN and Grn peptides were pulled down in the anti-PGRN IP (Fig. 1c ), we tested whether GBA can bind specific Grn peptides. N-terminal GFP-tagged Grn peptides or GFP-PGRN were co-transfected with myc-tagged GBA, followed by anti-GFP IP. While there was no obvious binding of granulin E, granulin F did interact with GBA in the cell lysate, as well as granulin A, although to a lesser extent ( Fig. 2a ). However, it is not clear whether these granulin peptides are folded correctly when expressed individually. We repeated the experiments with secreted granulins, which, having proceeded through the entire secretory pathway, may be more likely to be properly folded. In this instance, all the granulins except Grn G shows weak binding to GBA (Fig. 2b) .
PGRN deficiency leads to reduced GBA activities
To determine whether PGRN regulates GBA activities, we performed an in vitro GBA activity assay using a well-established fluorogenic GBA substrate, 4-Methylumbelliferyl β-D-glucopyranoside (4MU-β-glc) (45-47) ( Fig. 3) . GBA activity was measured in tissue lysates from 2-month-old WT and Grn -/mice, before obvious lysosomal phenotypes were observed. Liver and spleen lysates from Grn -/mice showed a significant decrease in GBA activity compared to WT controls (Fig. 3a,3b ). While the cerebrum and cerebellum showed a trend toward decreased GBA activity, it was not significant (Fig. 3c,   3d ). However, the midbrain, where we tend to observe the most severe defects in our knockout mouse line, showed a significant decrease in GBA activity (Fig. 3e ). Thus PGRN is likely to have cell type and tissue specific effects on GBA.
These results were confirmed using a recently developed ultrasensitive fluorescent probe, MDW941, which specifically reacts with active forms of the enzyme and has been shown to be sensitive enough to detect the activity of recombinant GBA in the attomolar range (48) (49) (50) . Using this probe, an even greater disparity between GBA activity in WT and Grn -/tissues was observed ( Fig. 4a-4e ). To verify that any changes in activity were not due to alterations in total GBA protein levels, SDS-PAGE and western blot of the tissue lysates were performed using antibodies specific to GBA (Fig. S1) , with no significant differences seen between groups (Fig. 4a-4e ).
Previously we showed that PGRN binds to prosaposin (PSAP) to facilitate each other's lysosomal trafficking (30, 51, 52) . PSAP is known to get cleaved in the lysosome to generate saposin peptides, of which saposins A and C are known activators of GBA (46, 53, 54) . This raises the possibility that the observed decrease in GBA activity with PGRN loss could be due to a decrease in PSAP or saposin peptides. However, we did not observe a significant change in PSAP or total saposins in the PGRN knockout tissues where GBA activity was reduced (Fig. 5) . Similarly, no obvious difference in saposin C levels in WT and PGRN deficient liver lysates were detected following immunoprecipitations using antibodies specific for saposin C (Fig. S2) . Unfortunately we cannot test saposin A levels due to a lack of specific antibodies.
With the changes we observed in GBA activity, and because PGRN and Grn E have been shown to directly activate CTSD in vitro, we wanted to test whether PGRN, Grn E, or Grn F could directly augment the activity of GBA. We performed a 4-MU activity assay of a pharmaceutical grade recombinant GBA (Cerezyme) with the addition of recombinant His-PGRN, GST-Grn E, GST-Grn F, His-SUMO-saposin C, or GST control. While the addition of saposin C greatly enhanced GBA activity, such effects were not observed with PGRN or granulin peptides (Fig. S3 ).
Discussion
In this study, we demonstrate a physical interaction between the FTLD-related protein, PGRN, and the lysosomal enzyme, GBA, consistent with previous reports (37, 38) . Additionally, among the granulin peptides, granulin F and to a lesser extent, granulin A, but not the previously reported granulin E, were shown to bind GBA in the cell lysate ( Fig. 2a ). All the secreted granulins except Grn G show weak binding to GBA (Fig. 2b) .
The previous studies examining the relationship between PGRN and GBA primarily utilized a chronic inflammation model based on the administration of ovalbumin (OVA) to WT and Grn -/mice over the course of multiple weeks. The authors showed that PGRN interacts with GBA and acts as a cochaperone of GBA and its trafficking receptor, lysosome membrane protein 2 (LIMP-2) (37, 38). Furthermore, LIMP-2 and GBA were shown to aggregate in the cytoplasm in PGRN deficient macrophages with experimentally induced chronic lung inflammation models (37, 38) . Unfortunately, we were unable to find a single commercial antibody that specifically recognize the endogenous GBA protein in immunostaining using WT and Gba -/mouse fibroblasts (data not shown), thus we cannot test whether there is a GBA trafficking defect with PGRN loss. Nevertheless, MDW41 labeling shows normal localization of active GBA in PGRN knockout fibroblasts (Fig. S4) .
The relationship between PGRN and GBA is complicated by a series of interrelated factors.
Two peptides derived from PSAP, saposin A and saposin C, are known activators of GBA (46, 53, 54) .
We have previously shown that PGRN and PSAP share a lysosomal co-trafficking relationship, wherein PGRN can carry PSAP to the lysosome via the receptor, sortilin, and PSAP can carry PGRN to the lysosome via the cation-independent mannose-6-phosphate receptor (CI-M6PR) or the low-density lipoprotein receptor-related protein 1 (LRP1) (30, 51, 52) . Additionally, PGRN has recently been shown to bind and modulate the activity of the lysosomal protease, cathepsin D (CTSD), which is the major contributor to proteolytic PSAP processing. Because of these factors, it is possible that PGRN deficiency results in an alteration in PSAP processing and production of saposin peptides, thereby affecting GBA activation. However, PSAP, total saposin levels and saposin C levels do not appear to change in PGRN deficient tissue lysates ( Fig. 3, Fig. S2 ), although we cannot rule out the possibility that saposin A levels might be affected.
We failed to detect any changes in GBA activity with the addition of recombinant PGRN or granulin peptides, but this does not entirely rule out the possibility of a direct activation of GBA by PGRN.
This may require further optimization of the conditions for the assay.
Another possibility is that PGRN indirectly affects GBA activity by changing the lysosomal environment. PGRN deficiency has been reported to affect lysosomal pH (55) , which could indirectly affect the activity of many lysosomal enzymes. Loss of PGRN also changes lipid contents of lysosomes (56) , which could also indirectly affect GBA activity. While the exact mechanism of our findings is currently unknown, and more work needs to be performed to sift through the somewhat muddled relationships of the proteins involved, it is clear that PGRN deficiency leads to reduced GBA activity. This is significant, as lysosomal dysfunction is a commonality between NCL and FTLD with GRN mutation. It is possible that the decreased activity of multiple lysosomal hydrolases, including GBA and CTSD, accounts for lysosomal dysfunction with GRN mutations.
Mutations and polymorphism in the GRN gene have also been associated with Parkinson's disease (PD) (57) (58) (59) (60) . In addition, reduced serum levels of PGRN were found to be associated with PD risk (61) . Moreover, viral expression of PGRN was shown to protect midbrain dopaminergic neurons and improve the locomotor function in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment to mimic PD in mouse models (62) . Interestingly, heterozygous mutations in GBA is one of the genetic determinants of PD(63) (64) . Our work on the regulation of GBA activity by PGRN might provide a mechanistic explanation underlining the association of PGRN and PD.
Conclusions
Our data support that PGRN deficiency leads to a reduction of GBA activity in vivo. Tissue lysates from 2-month-old WT and Grn -/mice were incubated with the MDW941 GBA activity probe. The samples were run on SDS-PAGE and MDW941 labeled GBA (active) was detected using a fluorescent scanner, then western blot was performed to assess total GBA protein levels. n = 5-6, ±SEM, *p value <0.05, **p-value <0.01, ns, not significant, Student's t-test. Figure 5 . PSAP and total saposin levels are not changed in PGRN deficient mice. Mouse tissue lysates from 2-month-old WT and Grn -/mice were assessed for PSAP and total saposin peptide levels, which were normalized to GAPDH. n = 5-6, ±SEM, ns, not significant, Student's t-test.
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